Scaling new heights in neurologic insights

We’re harnessing technological breakthroughs to transform how brain and spinal cord cancers are detected

As a team of neurosurgeons, scientists, and entrepreneurs, we founded Belay Diagnostics to help those diagnosed with brain or spinal cord tumors find the right path forward. Given the obstacles traditional methods of detecting brain or spinal cord malignancies present to both patients and their care teams, we see our proprietary molecular testing technology as a way to bridge the gap between today’s standards and a more clinically convenient future.

While there are options available to diagnose a malignant brain or spinal cord tumor, each presents potentially undesirable limitations in sensitivity, specificity, expense, and possible risks involved. By identifying and analyzing DNA in cerebrospinal fluid, our technology could lead the way to an economical, minimally invasive, and highly accurate alternative.

18K

Our Team

Chetan Bettegowda, MD, PhD

Co-founder, Board Member, Professor of Neurosurgery at Johns Hopkins University

Dr. Bettegowda has been practicing as a neurosurgeon at Johns Hopkins University since 2005, where he is an endowed professor of neurosurgery and oncology. He is an internationally recognized leader in brain cancer genetics and liquid biopsies. His work has helped define the molecular landscape of numerous nervous system cancers and he has been a pioneer in applying these discoveries for diagnostic benefit. He has published extensively in his respective field and leads the research setting the foundation for our molecular testing platform.

Brian Coe

Co-founder, CEO, Serial Entrepreneur

Brian Coe, MBA, co-founded two healthcare companies and successfully led them through commercialization prior to co-founding Belay Diagnostics with Dr. Bettegowda. He sold his first company, Litholink Corporation, to LabCorp in 2006, and then led Talis Biomedical through several funding rounds totaling $500M prior to taking the company public in early 2021. Brian also teaches as an adjunct professor of entrepreneurship at the University of Chicago’s Booth School of Business.

Tim Webster

Senior Vice President, Operations

Tim Webster has more than 30 years of laboratory management and leadership experience. Trained at the Royal Army Medical College in London, he led teams in community hospitals, academic medical centers at Yale and Beth Israel Deaconess, and commercial laboratories as part of Aurora Diagnostics, Progenity Inc, and Baylor Genetics. He was recognized with a national Leadership in Management award in 2005, and is a regular speaker at national and international symposiums and conferences on laboratory practice.

Alex De los Reyes

Vice President, Sales & Marketing

Alex De los Reyes has 20 years of sales leadership experience in the life sciences industry, including 14 years at LabCorp and two years at Talis Biomedical, where he was recruited to build out the commercial sales organization from the ground up. Alex has successfully led sales organizations with a national footprint from inception through pre-commercial deployment (including remote recruitment and training during the pandemic). He is very passionate about finding exceptional talent and assembling world-class sales organizations that deliver exceptional results.

Manu Bettegowda

Co-founder, Board Member, Managing Partner

Manu Bettegowda has been at Olympus Partners since 1998 and became a partner in 2004 before being promoted to managing partner in 2021. He has been involved in investing in numerous companies in a variety of fields, including Symmetry Medical, Pregis Corp., and Tank Holdings.

Jonathan Dudley, MD

Co-founder, Assistant Professor of Pathology at Johns Hopkins University

Dr. Jon Dudley is a molecular pathologist and runs an independent research lab at Johns Hopkins University, where he is an assistant professor of Pathology and Oncology. He is the recipient of the Young Investigator Award from the Association for Molecular Pathology and the Benjamin Castleman Award from the United States and Canadian Academy of Pathology, and his research focuses on molecular diagnostic assay development.

Chris Douville, PhD

Co-founder, Assistant Professor of Oncology at Johns Hopkins University

Chris Douville is an assistant professor in the Department of Oncology at Johns Hopkins University within the Division of Quantitative Sciences. His research group uses computational models to design, interpret, and improve molecular diagnostics for earlier detection of cancer and monitoring of minimal residual disease. His work has resulted in several bioinformatics software packages, and he is an active member of the AI-X colloquium.

Chetan Bettegowda, MD, PhD

Co-founder, Board Member, Professor of Neurosurgery at Johns Hopkins University

Dr. Bettegowda has been practicing as a neurosurgeon at Johns Hopkins University since 2005, where he is an endowed professor of neurosurgery and oncology. He is an internationally recognized leader in brain cancer genetics and liquid biopsies. His work has helped define the molecular landscape of numerous nervous system cancers and he has been a pioneer in applying these discoveries for diagnostic benefit. He has published extensively in his respective field and leads the research setting the foundation for our molecular testing platform.

Brian Coe

Co-founder, CEO, Serial Entrepreneur

Brian Coe, MBA, co-founded two healthcare companies and successfully led them through commercialization prior to co-founding Belay Diagnostics with Dr. Bettegowda. He sold his first company, Litholink Corporation, to LabCorp in 2006, and then led Talis Biomedical through several funding rounds totaling $500M prior to taking the company public in early 2021. Brian also teaches as an adjunct professor of entrepreneurship at the University of Chicago’s Booth School of Business.

Tim Webster

Senior Vice President, Operations

Tim Webster has more than 30 years of laboratory management and leadership experience. Trained at the Royal Army Medical College in London, he led teams in community hospitals, academic medical centers at Yale and Beth Israel Deaconess, and commercial laboratories as part of Aurora Diagnostics, Progenity Inc, and Baylor Genetics. He was recognized with a national Leadership in Management award in 2005, and is a regular speaker at national and international symposiums and conferences on laboratory practice.

Alex De los Reyes

Vice President, Sales & Marketing

Alex De los Reyes has 20 years of sales leadership experience in the life sciences industry, including 14 years at LabCorp and two years at Talis Biomedical, where he was recruited to build out the commercial sales organization from the ground up. Alex has successfully led sales organizations with a national footprint from inception through pre-commercial deployment (including remote recruitment and training during the pandemic). He is very passionate about finding exceptional talent and assembling world-class sales organizations that deliver exceptional results.

Manu Bettegowda

Co-founder, Board Member, Managing Partner

Manu Bettegowda has been at Olympus Partners since 1998 and became a partner in 2004 before being promoted to managing partner in 2021. He has been involved in investing in numerous companies in a variety of fields, including Symmetry Medical, Pregis Corp., and Tank Holdings.

Jonathan Dudley, MD

Co-founder, Assistant Professor of Pathology at Johns Hopkins University

Dr. Jon Dudley is a molecular pathologist and runs an independent research lab at Johns Hopkins University, where he is an assistant professor of Pathology and Oncology. He is the recipient of the Young Investigator Award from the Association for Molecular Pathology and the Benjamin Castleman Award from the United States and Canadian Academy of Pathology, and his research focuses on molecular diagnostic assay development.

Chris Douville, PhD

Co-founder, Assistant Professor of Oncology at Johns Hopkins University

Chris Douville is an assistant professor in the Department of Oncology at Johns Hopkins University within the Division of Quantitative Sciences. His research group uses computational models to design, interpret, and improve molecular diagnostics for earlier detection of cancer and monitoring of minimal residual disease. His work has resulted in several bioinformatics software packages, and he is an active member of the AI-X colloquium.


Participation by Chris Douville, PhD, Jonathan Dudley, MD, and Chetan Bettegowda, MD, PhD, does not constitute or imply endorsement by the Johns Hopkins University or the Johns Hopkins Hospital and Health System.

"*" indicates required fields